IRLAB Initiates Dosing with IRL757 in the P-I Study for Apathy

Share this

IRLAB Initiates Dosing with IRL757 in the P-I Study for Apathy


  • IRLAB has begun dosing with IRL757 in the P-I trial assessing safety, tolerability & PK among healthy individuals in 2 parts; 1st part administers SAD & the 2nd part administers MAD. The study is anticipated to conclude in 2024
  • It has partnered with Otsuka's MSRD to develop IRL757, retaining full ownership & patent rights to IRL757 plus receiving $3M upfront & $5.5M milestones. MSRD can choose to expand the partnership based on specific triggering events, pending negotiation of a new agreement. If collaboration doesn't expand, MSRD may receive low single-digit royalties under certain conditions
  • Furthermore, the company secured full project funding through clinical PoC studies with Michael J. Fox Foundation granting over $1.86M to conduct its P-I study

Ref: IRLAB Therapeutics | Image:IRLAB Therapeutics

Related News:- IRLAB and McQuade Center for Strategic Research and Development (MSRD) Collaborate to Develop IRL757 for Apathy

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions